Many of Illumina shareholders have grown increasingly frustrated with Chief Executive Francis deSouza’s pursuit of Grail. The decision to close the $7.1 billion acquisition in August 2021 despite regulators’ objections baffled many investors and is largely to blame for cutting the company’s market capitalization in half. Grail, which makes cancer-detection tests, lost about $600 million last year, cutting into Illumina’s profit.